Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23373683 | 0.87 | KMT2A (0.31) | — | |
| SCHEMBL22820873 | 0.80 | CD274 (0.33) | CD274 | |
| SCHEMBL20698607 | 0.78 | CD274 (0.32) | CD274 | |
| SCHEMBL20698400 | 0.78 | CD274 (0.31) | CD274 | |
| SCHEMBL22890895 | 0.78 | HTT (0.39) | HTT | |
| SCHEMBL20980937 | 0.76 | CD274 (0.31) | CD274 | |
| SCHEMBL23713760 | 0.75 | — | — | |
| SCHEMBL24792370 | 0.71 | HRH3 (0.43) | — | |
| SCHEMBL22820872 | 0.71 | — | — | |
| SCHEMBL22731574 | 0.70 | HRH3 (0.37) | CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020257549-A2 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-10568874-B2 | Indane-amines as PD-L1 antagonists | CHEMOCENTRYX, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190282555-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CHEMOCENTRYX, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282555-A1 | INDANE-AMINES AS PD-L1 ANTAGONISTS | CD274, PDCD1LG2, PDCD1 | CD274 1/4885HTT 3257/4885 |
| US-10568874-B2 | Indane-amines as PD-L1 antagonists | CD274, PDCD1LG2, PDCD1 | CD274 1/4885HTT 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.